4.5 Review

Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19

期刊

HYPERTENSION RESEARCH
卷 45, 期 7, 页码 1147-1153

出版社

SPRINGERNATURE
DOI: 10.1038/s41440-022-00922-3

关键词

Coronavirus disease 2019; Renin-angiotensin system; Angiotensin-converting enzyme 2; Angiotensin-converting enzyme inhibitor; Angiotensin II type-1 receptor blocker

向作者/读者索取更多资源

This article summarizes the potential effects of RAS inhibitors and their impact on COVID-19, indicating that further research is needed to confirm their role.
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the possible roles of renin-angiotensin system (RAS) inhibitors in COVID-19 have been debated as favorable, harmful, or neutral. Angiotensin-converting enzyme 2 (ACE2) not only is the entry route of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but also triggers a major mechanism of COVID-19 aggravation by promoting tissue RAS dysregulation, which induces a hyperinflammatory state in several organs, leading to lung injury, hematological alterations, and immunological dysregulation. ACE inhibitors and angiotensin II type-1 receptor blockers (ARBs) inhibit the detrimental hyperactivation of the RAS by SARS-CoV-2 and increase the expression of ACE2, which is a counter-regulator of the RAS. Several studies have investigated the beneficial profile of RAS inhibitors in COVID-19; however, this finding remains unclear. Further prospective studies are warranted to confirm the role of RAS inhibitors in COVID-19. In this review, we summarize the potential effects of RAS inhibitors that have come to light thus far and review the impact of RAS inhibitors on COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据